Meibomian gland dysfunction (MGD), Demodex folliculorum blepharitis, dry eye, ocular surface disease Eye Diseases Meibomian gland dysfunction (MGD), Demodex folliculorum blepharitis, dry eye, ocular surface disease
Conditions
Interventions
After filling out a symptom questionnaire and having an eye exam, participants are randomly allocated to one of three groups. Participants are randomised by choosing a number from 1-60. Each number co
Sponsors
Dublin Institute of Technology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Have G1 meibomian gland dysfunction according to the diagnostic subcommittee of the International Workshop on Meibomian Gland Dysfunction 2. Be 18 years of age or older
Exclusion criteria
Exclusion criteria: 1. Undergoing treatment for meibomian gland dysfunction, or have used treatment within the past 6 months 2. Contact lens wearers 3. Ocular surgery within the past 6 months 4. Systemic disease or use of topical/systemic medication known to affect the eyes 5. Presence of ocular disease except for MGD and blepharitis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Meibomian Gland Dysfunction (MGD) grade/severity is measured according to recommendations of the diagnostic subcommittee of the International Workshop on Meibomian Gland Dysfunction at baseline, 2 weeks, 4 weeks and 8 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Association between MGD and ocular Demodex folliculorum infestion is assessed using prevalence of ocular Demodex folliculorum infestation in the lash samples at baseline 2. Effectiveness of warm compresses in treating ocular Demodex folliculorum infestation is assessing using the quantity of Demodex in lash sampels at baseline, 2 weeks, 4 weeks and 8 weeks | — |
Countries
Ireland
Contacts
Public ContactOrla Murphy
Outcome results
None listed